Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Deep Learning Artificial Intelligence and Restriction Spectrum Imaging for Patient-level Detection of Clinically Significant Prostate Cancer on Biparametric Magnetic Resonance Imaging
0
Zitationen
31
Autoren
2026
Jahr
Abstract
Background and objective: alone. Methods: for heterogeneity) were generated, and the area under the ROC curve (AUC) and sensitivity, were compared, as well as specificity at fixed sensitivity of 0.90. Calibration, decision-curve, and reclassification analyses (net reclassification improvement and integrated discrimination improvement) were performed. Codes used in developing the DL model are available on GitHub (https://github.com/ESONG1999/Deep-learning-AI-and-RSI-for-patient-level-detection-of-csPCa-on-MRI). Key findings and limitations: + PI-RADS, and 0.03 (95% CI 0.03-0.04) for DL + PI-RADS. Conclusions and clinical implications: and the best DL model demonstrated comparable performance to PI-RADS alone. Addition of either model to PI-RADS significantly enhanced patient-level detection of csPCa in comparison to PI-RADS alone. Limitations include biopsy as an imperfect reference, the exclusion of hip implant cases, lack of external calibration, limited RSI availability, and missing case-level information for individual radiologists and their expertise. Patient summary: We looked at whether adding advanced scan data (ASD) and artificial intelligence (AI) models to radiologist assessments of MRI (magnetic resonance imaging) scans was better in detecting aggressive prostate cancer (PCa). We found that adding AI models or ASD to standard scan scores improved cancer detection in comparison to standard scores alone. The results suggest that combining radiologist expertise with AI and ASD may help in earlier identification of more patients with csPCa.
Ähnliche Arbeiten
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
2004 · 5.712 Zit.
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
2010 · 5.465 Zit.
Decision Curve Analysis: A Novel Method for Evaluating Prediction Models
2006 · 5.229 Zit.
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
2012 · 4.555 Zit.
Biochemical Outcome After Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer
1998 · 4.500 Zit.
Autoren
- Yuze Song
- Mariluz Rojo Domingo
- Christopher C. Conlin
- Deondre D. Do
- Madison T. Baxter
- Anna Dornisch
- George Xu
- Aditya Bagrodia
- Tristan Barrett
- Mukesh Harisinghani
- Gary Hollenberg
- Sophia C. Kamran
- Christopher J. Kane
- Dimitri A. Kessler
- Joshua Kuperman
- Kanglung Lee
- Michael A. Liss
- Daniel J. A. Margolis
- P. Murphy
- Nabih Nakrour
- Truong Ngyuen
- Thomas L. Osinski
- Rebecca Rakow-Penner
- Shoumik Roychowdhury
- Ahmed S Shabik
- Shaun Trecarten
- Natasha Wehrli
- Eric Weinberg
- Sean A. Woolen
- Anders M. Dale
- Tyler M Seibert
Institutionen
- University of California San Diego(US)
- La Jolla Bioengineering Institute(US)
- University of Cambridge(GB)
- Massachusetts General Hospital(US)
- University of Rochester Medical Center(US)
- Artificial Intelligence Research Institute(ES)
- Artificial Intelligence in Medicine (Canada)(CA)
- Universitat de Barcelona(ES)
- Cornell University(US)
- University of California, Berkeley(US)
- The University of Texas Health Science Center at San Antonio(US)
- University of California, San Francisco(US)